Literature DB >> 75739

In vitro induction of tumour-specific immunity V. Detection of common antigenic determinatnts of murine fibrosarcomas.

R C Burton, N L Warner.   

Abstract

Two 3-methylcholanthrene and a spontaneous BALB/c fibrosarcoma were examined for tumour-associated antigens (TAA) by in vivo and in vitro induction of tumour-immune responses. When BALB/c mice were immunized to these fibrosarcomas by surgical tumour removal, cross-reacting tumour-associated transplantation antigens (TATA) were detected on all 3 tumours. Cytotoxic effector cells (CL) were then induced in vitro by co-culture of BALB/c spleen cells with the spontaneous, or one of the carcinogen-induced fibrosarcomas. These CL were shown to be cytotoxic T cells (Tc) and to be directed against cross-reacting TAA on all 3 tumours, by two in vitro 51Cr-release assay systems, direct 51Cr-release cytotoxicity and cellular competitive inhibition of 51Cr release. Further studies demonstrated that the fibrosarcoma TAA involved in in vitro induction of Tc were not present on normal adult or foetal tissues. A secondary cytotoxic response was also detected in vitro when spleen cells from mice immunized to a carcinogen-induced fibrosarcoma were tested. The patterns of cross-reactivity detected by the in vivo and primary in vitro tumour-immune responses suggested that the TAA detected in vivo (TATA) were not identical to the TAA detected in vitro.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 75739      PMCID: PMC2009573          DOI: 10.1038/bjc.1978.24

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  35 in total

1.  Inhibition of syngeneic fibrosarcoma growth by lymphocytes sensitized on tumor-cell monolayers in the presence of the thymic humoral factor.

Authors:  M Small; N Trainin
Journal:  Int J Cancer       Date:  1975-06-15       Impact factor: 7.396

2.  Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homografts.

Authors:  H J WINN
Journal:  J Immunol       Date:  1961-02       Impact factor: 5.422

3.  Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host.

Authors:  G KLEIN; H O SJOGREN; E KLEIN; K E HELLSTROM
Journal:  Cancer Res       Date:  1960-12       Impact factor: 12.701

4.  Tumor immunity to murine plasma cell tumors. III. Detection of common and unique tumor-associated antigens on BALB/c, C3H, and NZB plasmacytomas by in vivo and in vitro induction of tumor-immune responses.

Authors:  R C Burton; N L Warner
Journal:  J Natl Cancer Inst       Date:  1977-03       Impact factor: 13.506

5.  Comparative in vitro sensitivity of twom methylcholanthrene-induced murine sarcoma lines to humoral and cellular immune cytotoxicity.

Authors:  G Bataillon; H Pross; G Klein
Journal:  Int J Cancer       Date:  1975-08-15       Impact factor: 7.396

6.  Relationship of tumor immunogenicity to concentration of the oncogen.

Authors:  R T Prehn
Journal:  J Natl Cancer Inst       Date:  1975-07       Impact factor: 13.506

7.  Detection of private and common tumor-associated antigens in murine sarcomas induced by different chemical carcinogens.

Authors:  D Fritze; D H Kern; J A Humme; C R Drogemuller; Y H Pilch
Journal:  Int J Cancer       Date:  1976-01-15       Impact factor: 7.396

8.  Specific stimulatory and cytotoxic effects of lymphocytes sensitized in vitro to either alloantigens or tumor antigens.

Authors:  M A Kall; I Hellström
Journal:  J Immunol       Date:  1975-03       Impact factor: 5.422

9.  Cellular basis for the immune response to methylcholanthrene-induced tumors in mice. Heterogeneity of effector cells.

Authors:  R Kearney; A Basten; D S Nelson
Journal:  Int J Cancer       Date:  1975-03-15       Impact factor: 7.396

10.  Studies on the effector cell of anti-tumour immunity in a chemically induced mouse tumour system.

Authors:  R B Whitney; J G Levy; A G Smith
Journal:  Br J Cancer       Date:  1975-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.